Company registration number 03446822 (England and Wales)
ADVINIA HEALTH CARE LIMITED
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
ADVINIA HEALTH CARE LIMITED
COMPANY INFORMATION
Directors
Dr S Kanoria
Mrs S Kanoria
Mr A Verma
Mr MW Freer
(Appointed 11 September 2024)
Company number
03446822
Registered office
Gateway House (First Floor)
324 Regents Park Road
London
N3 2LN
Auditor
Taylor Associates
1st Floor Gallery Court
28 Arcadia Avenue
London
N3 2FG
ADVINIA HEALTH CARE LIMITED
CONTENTS
Page
Strategic report
1 - 3
Directors' report
4 - 6
Independent auditor's report
7 - 10
Profit and loss account
11
Group statement of comprehensive income
12
Group balance sheet
13
Company balance sheet
14
Group statement of changes in equity
15
Company statement of changes in equity
16
Group statement of cash flows
17
Notes to the financial statements
18 - 37
ADVINIA HEALTH CARE LIMITED
STRATEGIC REPORT
FOR THE YEAR ENDED 31 MARCH 2025
- 1 -

The directors present the group strategic report for the year ended 31 March 2025.

Review of the business

Advinia Health Care Limited (the “company”) is a leading care home operator. The company and its subsidiaries (the “group” or “Advinia”) operate 22 care homes in England and 13 care homes in Scotland, with approximately 3,300 beds in total, currently providing employment to more than 2,800 staff.

 

The group turnover and other operating income in the financial year ended 31 March 2025 amounted to £97,394,339 (2024: £97,150,652). The management team focused on optimising resident safety and balancing costs improving profitability.

 

Approximately 80% of group revenues are from state-funded Local Authorities and CCGs, which provide the group with government secured income with the remaining 20% of revenues from self-funding residents.

Principal risks and risk management

Credit risk

The group’s credit risk is limited as its trade receivables are from government-funded bodies such as Local Authorities, CCGs and NHS trusts, who reliably pay on time. Self-funded residents pay in advance by direct debit. There is regular monitoring and reviews of receivables by the finance and operations teams.

 

Liquidity risk

The group maintains liquidity and sufficient working capital for its ongoing operations and future developments through operating cash flows and facilities provided by its stakeholders.

 

Operational risk

The operation of the company’s care homes is managed by an experienced team of senior management, regional teams and local care home managers. There are clear governance processes in place from care home level to board level to ensure regular performance reviews are undertaken across the group on a frequent basis.

 

Reputational risk

Reputational risk is managed through mandatory and specialist training and development of staff. All care staff are subject to rigorous recruitment checks via the Disclosure and Barring Service and Protecting Vulnerable Groups membership. The group has an online mandatory training system for all staff and clear induction processes.

Industry overview

Despite the economic environment, the longer-term demand remains strong for residential care homes, principally driven by the continued rising numbers of people over the age of 85. The pandemic has further highlighted the critical role played by the social care sector. Over recent years there has been a reduction in care home bed provision and the group is well positioned to further grow, both organically and through M&A activity, and the directors believe there will be opportunities in the group's segment of the market for further consolidation and scaling.

 

In the short-term the directors have strategies in place to ensure continued profitable growth is achieved by deploying refurbishment capex where local demand warrants such spend to further drive back occupancy. In addition, the directors have identified redevelopment opportunities within the group to expand capacity at existing homes and reposition units within existing homes to provide specialist care provision, attracting higher fee rates.

 

The directors continue to remain hopeful that the government will find a political consensus to reform social care funding, providing a more equitable basis for social care provision, taking account of the full costs of providing high-quality care.

Key performance indicators

The group monitors key financial and non-financial KPIs on a weekly and monthly basis through dashboard reporting. Occupancy and AWF remain key KPIs for the group. There is continued focus by management on ensuring resident fee rates are appropriate for their care needs and rates are optimised with local authorities to protect residents. All KPIs have improved, resulting in better profitability and quality.

ADVINIA HEALTH CARE LIMITED
STRATEGIC REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 2 -
Outlook

As highlighted above the outlook for the care sector is promising due to its impact on hospital bed blocking and an increasing ageing population with higher dependencies.

Inflation and Energy costs

The Group has a strategic procurement plan in place which actively monitors both the quality of its suppliers and market price of good and services on a continuous basis. This includes constant benchmarking against the market and the ability to tender as need, in most cases at least annually.

 

Given the current inflationary pressures most contracts are not long term and energy markets are monitored throughout the year to take advantage of price movements.

 

Since the year end, key suppliers for food and energy have been retendered and changed as part of the ongoing programme.

 

Promote the success of the company
The directors of the group have had regard to a variety of stakeholders other than the Group's shareholders when making strategic business decisions. Management is committed to engaging and reflecting on stakeholder needs through regular dialogue and communication. The directors recognise the unique nature of relationships with different key stakeholders and the dependencies of different elements of the business upon them. Relationships with key stakeholders are managed through relevant engagement activities in order to inform the board in their decision making and delivery of strategy.
Regulation Compliance

The Care Quality Commission ("CQC") and The Scottish Care Inspectorate ("CI") are independent regulators of health and social care in England and Scotland, respectively. The CQC and CI regularly inspect our care homes and we have robust internal audit processes to ensure compliance.

 

The group monitors operational KPIs in relation to regulatory and health and safety compliance, key ones being:

 

 

Over the last few years the group has invested in and deployed technology to enhance its operations and provide a platform for future scalability. The group has deployed RADAR (care quality assurance and reporting software), eMAR (electronic medication administration), Time & Attendance (biometric colleague time recording) and is currently implementing Person Centred Software (PCS) which allows nurses and carers to record resident interactions and care plans digitally, providing ease of audit and enhanced accuracy.

Local Authorities

Approximately 80% of group revenues are from state-funded Local Authorities and CCGs, which provide the group with steady, secure and timely cash inflows with the remaining 20% of revenues from higher fee-paying, self-funding residents.

Employees

The Group employ over 2,800 employees operating in care home sectors. Maintaining an engaged and motivated workforce driven by the desire to their development is a key priority for the Group. Through recruiting and retaining exceptional talent the Group aim to build industry leading teams at forefront of care sectors.

 

Health and Safety is a main focus for the Group, with the group operating a Health and Safety policy across all homes and wellbeing support for all employees. Continued training and development are also offered to staff through internal/​external training providers to ensure staff development.

ADVINIA HEALTH CARE LIMITED
STRATEGIC REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 3 -
Employee involvement

The group's policy is to consult and discuss with employees, through unions, staff councils and at meetings, matters likely to affect employees' interests.

 

Information about matters of concern to employees is given through information bulletins and reports which seek to achieve a common awareness on the part of all employees of the financial and economic factors affecting the group's performance.

 

There is no employee share scheme at present, but the directors are considering the introduction of such a scheme as a means of further encouraging the involvement of employees in the company's performance.

 

The directors of the Group take into account the interest of its stakeholders during key decision as part of their duty to promote the success of the Group. The directors acts in a way they consider, in good faith, would be most likely to promote the success of the Group for the benefits of its members as a whole, and in doing so have regard to the following factors in relation to Section 172(1);

 

 

On behalf of the board

Dr S Kanoria
Director
24 December 2025
ADVINIA HEALTH CARE LIMITED
DIRECTORS' REPORT
FOR THE YEAR ENDED 31 MARCH 2025
- 4 -

The directors present their annual report and financial statements for the year ended 31 March 2025.

Principal activities

The principal activity of the group continued to be that of the provision and management of long term care facilities for the elderly.

Results and dividends

The results for the year are set out on page 11.

No ordinary dividends were paid. The directors do not recommend payment of a further dividend.

Directors

The directors who held office during the year and up to the date of signature of the financial statements were as follows:

Dr S Kanoria
Mrs S Kanoria
Mr A Verma
Mr MW Freer
(Appointed 11 September 2024)
Supplier payment policy

The group's current policy concerning the payment of trade creditors is to follow the CBI's Prompt Payers Code (copies are available from the CBI, Centre Point, 103 New Oxford Street, London WC1A 1DU).

 

The group's current policy concerning the payment of trade creditors is to:

 

Trade creditors of the group at the year end were equivalent to 28 day's purchases, based on the average daily amount invoiced by suppliers during the year.

Disabled persons

Applications for employment by disabled persons are always fully considered, bearing in mind the aptitudes of the applicant concerned. In the event of members of staff becoming disabled, every effort is made to ensure that their employment within the group continues and that the appropriate training is arranged. It is the policy of the group that the training, career development and promotion of disabled persons should, as far as possible, be identical to that of other employees.

Employee involvement

The group's policy is to consult and discuss with employees, through unions, staff councils and at meetings, matters likely to affect employees' interests.

 

Information about matters of concern to employees is given through information bulletins and reports which seek to achieve a common awareness on the part of all employees of the financial and economic factors affecting the group's performance.

Auditor

In accordance with the company's articles, a resolution proposing that Taylor Associates be reappointed as auditor of the group will be put at a General Meeting.

ADVINIA HEALTH CARE LIMITED
DIRECTORS' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 5 -
Energy and carbon report

As the group has not consumed more than 40,000 kWh of energy in this reporting period, it qualifies as a low energy user under these regulations and is not required to report on its emissions, energy consumption or energy efficiency activities.

Statement of directors' responsibilities

The directors are responsible for preparing the Annual Report and the financial statements in accordance with applicable law and regulations.

 

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the group and company, and of the profit or loss of the group for that period. In preparing these financial statements, the directors are required to:

 

 

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the group’s and company’s transactions and disclose with reasonable accuracy at any time the financial position of the group and company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the group and company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Statement of disclosure to auditor

So far as each person who was a director at the date of approving this report is aware, there is no relevant audit information of which the auditor of the company is unaware. Additionally, the directors individually have taken all the necessary steps that they ought to have taken as directors in order to make themselves aware of all relevant audit information and to establish that the auditor of the company is aware of that information.

Going concern

Having reviewed the group financial forecasts and expected future cash flows, the directors have a reasonable expectation that the company and group have adequate resources available to it to continue in operational existence for the foreseeable future, a period of not less than 12 months from the date of signing of these financial statements. The directors have considered the impact of inflation in their going concern assessment and have forecast occupancy growth on a prudent basis. The group meets its day to day working capital requirements through operating cash flows and through facilities provided by its stakeholders. If necessary, shareholders are willing to provide further financial support as they have done in the past.

 

The directors have therefore continued to adopt the going concern basis in preparing the financial statements for the year ended 31 March 2025.

 

ADVINIA HEALTH CARE LIMITED
DIRECTORS' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 6 -
On behalf of the board
Dr S Kanoria
Director
24 December 2025
ADVINIA HEALTH CARE LIMITED
INDEPENDENT AUDITOR'S REPORT
DRAFT
TO THE MEMBERS OF ADVINIA HEALTH CARE LIMITED
- 7 -
Opinion

We have audited the financial statements of Advinia Health Care Limited (the 'parent company') and its subsidiaries (the 'group') for the year ended 31 March 2025 which comprise the group profit and loss account, the group statement of comprehensive income, the group balance sheet, the company balance sheet, the group statement of changes in equity, the company statement of changes in equity, the group statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the group and parent company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

 

The group meets its day to day working capital requirements through operating cash flows and through facilities provided by its stakeholders. If necessary, shareholders are willing to provide further financial support as they have done in the past.

 

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's and parent company’s ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

 

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

 

We have nothing to report in this regard.

ADVINIA HEALTH CARE LIMITED
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
DRAFT
TO THE MEMBERS OF ADVINIA HEALTH CARE LIMITED
- 8 -

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of our audit:

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the group and the parent company and their environment obtained in the course of the audit, we have not identified material misstatements in the strategic report or the directors' report.

 

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

Responsibilities of directors

As explained more fully in the directors' responsibilities statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the directors are responsible for assessing the parent company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the parent company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud.

 

The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

ADVINIA HEALTH CARE LIMITED
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
DRAFT
TO THE MEMBERS OF ADVINIA HEALTH CARE LIMITED
- 9 -

We planned our audit so that we have a reasonable expectation of detecting material misstatements in the financial statements resulting from irregularities, fraud or non-compliance with law or regulations.

 

In identifying and assessing risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, our procedures included the following:

To address the risk of fraud through management bias and override of controls, we:

 

In response to the risk of irregularities and non compliance with laws and regulations, we designed procedures which included, but are not limited to:

 

The test nature and other inherent limitations of an audit, together with the inherent limitations of any accounting and internal control system, mean that there is an unavoidable risk that some material misstatements in respect of irregularities may remain undiscovered even though the audit is properly planned and performed in accordance with ISAs (UK). Furthermore, the further removed those laws and regulations are from financial transactions, the less likely it is that we would become aware of non-compliance. Our examination should therefore not be relied upon to disclose all such material misstatements or frauds, errors or instances of non-compliance that might exist. The responsibility for safeguarding the assets of the company and for the prevention and detection of fraud, error and non-compliance with law or regulations rests with the directors.

A further description of our responsibilities is available on the Financial Reporting Council’s website at: https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Use of our report

This report is made solely to the company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company’s members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company’s members as a body, for our audit work, for this report, or for the opinions we have formed.

ADVINIA HEALTH CARE LIMITED
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
DRAFT
TO THE MEMBERS OF ADVINIA HEALTH CARE LIMITED
- 10 -
Asif Hassan FCA
For and on behalf of Taylor Associates
24 December 2025
Chartered Accountants
Statutory Auditor
1st Floor Gallery Court
28 Arcadia Avenue
London
N3 2FG
ADVINIA HEALTH CARE LIMITED
GROUP PROFIT AND LOSS ACCOUNT
FOR THE YEAR ENDED 31 MARCH 2025
- 11 -
2025
2024
Notes
£
£
Turnover
3
97,394,339
97,150,651
Cost of sales
(74,070,570)
(74,803,929)
EBITDAM
23,323,769
22,346,722
Administrative expenses
4
(18,455,567)
(14,359,151)
Other operating income
41,489
109,522
Net profit
5
4,909,691
8,097,093
Interest receivable and similar income
9
38,589
37,030
Interest payable and similar expenses
10
(3,699,436)
(5,433,415)
Amounts written off investments
11
(165,444)
(745,978)
Profit before taxation
1,083,400
1,954,730
Tax on profit
12
(567,210)
(201,075)
Profit for the financial year
516,190
1,753,655
Profit for the financial year is all attributable to the owners of the parent company.
Non-GAAP measure: (Adjusted) Earnings Before Interest, Tax, Depreciation and Amortisation
(Adjusted EBITDA)
Analysed as:
Operating profit analysed above
4,909,691
8,097,093
Add back: depreciation of tangible fixed assets and amortisation
6,267,379
5,801,607
Deduct: amortisation of negative goodwill
-
(2,959,274)
EBITDA
11,177,070
10,939,426
add back: Non-recurring items
13
3,237,426
3,075,606
Adjusted EBITDA
14,414,496
14,015,032
ADVINIA HEALTH CARE LIMITED
GROUP STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 31 MARCH 2025
- 12 -
2025
2024
£
£
Profit for the year
516,190
1,753,655
Other comprehensive income
Revaluation of tangible fixed assets
19,708,457
12,145,524
Tax relating to other comprehensive income
(4,431,124)
(3,166,201)
Other comprehensive income for the year
15,277,333
8,979,323
Total comprehensive income for the year
15,793,523
10,732,978
Total comprehensive income for the year is all attributable to the owners of the parent company.
ADVINIA HEALTH CARE LIMITED
GROUP BALANCE SHEET
AS AT 31 MARCH 2025
31 March 2025
- 13 -
2025
2024
Notes
£
£
£
£
Fixed assets
Negative goodwill
14
(1)
(1)
Other intangible assets
14
1,577,606
1,964,336
Total intangible assets
1,577,605
1,964,335
Tangible assets
15
156,015,772
137,839,222
157,593,377
139,803,557
Current assets
Debtors
18
5,944,595
7,781,637
Cash at bank and in hand
4,345,239
3,374,755
10,289,834
11,156,392
Creditors: amounts falling due within one year
19
(17,379,646)
(18,482,223)
Net current liabilities
(7,089,812)
(7,325,831)
Total assets less current liabilities
150,503,565
132,477,726
Creditors: amounts falling due after more than one year
20
(53,830,574)
(56,461,281)
Provisions for liabilities
Deferred tax liability
22
23,298,376
18,435,352
(23,298,376)
(18,435,352)
Net assets
73,374,615
57,581,093
Capital and reserves
Called up share capital
24
5,000,000
5,000,000
Revaluation reserve
53,296,057
38,018,724
Other reserves
38,304
38,304
Profit and loss reserves
15,040,254
14,524,065
Total equity
73,374,615
57,581,093
The financial statements were approved by the board of directors and authorised for issue on 24 December 2025 and are signed on its behalf by:
24 December 2025
Dr S Kanoria
Director
Company registration number 03446822 (England and Wales)
ADVINIA HEALTH CARE LIMITED
COMPANY BALANCE SHEET
AS AT 31 MARCH 2025
31 March 2025
- 14 -
2025
2024
Notes
£
£
£
£
Fixed assets
Intangible assets
1,289,585
1,694,473
Tangible assets
15
32,270,783
26,968,410
Investments
16
57,538,498
57,536,198
91,098,866
86,199,081
Current assets
Debtors
18
788,928
477,855
Cash at bank and in hand
3,405,237
1,847,091
4,194,165
2,324,946
Creditors: amounts falling due within one year
19
(4,594,132)
(5,243,922)
Net current liabilities
(399,967)
(2,918,976)
Total assets less current liabilities
90,698,899
83,280,105
Creditors: amounts falling due after more than one year
20
(69,123,398)
(65,769,336)
Provisions for liabilities
Deferred tax liability
22
4,077,551
2,734,877
(4,077,551)
(2,734,877)
Net assets
17,497,950
14,775,892
Capital and reserves
Called up share capital
24
5,000,000
5,000,000
Revaluation reserve
11,913,116
9,180,792
Profit and loss reserves
584,834
595,100
Total equity
17,497,950
14,775,892

As permitted by s408 Companies Act 2006, the company has not presented its own profit and loss account and related notes. The company’s loss for the year was £10,266 (2024 - £782,763 loss).

The financial statements were approved by the board of directors and authorised for issue on 24 December 2025 and are signed on its behalf by:
24 December 2025
Dr S Kanoria
Director
Company registration number 03446822 (England and Wales)
ADVINIA HEALTH CARE LIMITED
GROUP STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 MARCH 2025
- 15 -
Share capital
Revaluation reserve
Merger reserve
Profit and loss reserves
Total
£
£
£
£
£
Balance at 1 April 2023
5,000,000
29,039,401
38,304
12,770,410
46,848,115
Year ended 31 March 2024:
Profit for the year
-
-
-
1,753,655
1,753,655
Other comprehensive income:
Revaluation of tangible fixed assets
-
12,145,524
-
-
12,145,524
Tax relating to other comprehensive income
-
(3,166,201)
-
-
0
(3,166,201)
Total comprehensive income
-
8,979,323
-
1,753,655
10,732,978
Balance at 31 March 2024
5,000,000
38,018,724
38,304
14,524,065
57,581,093
Year ended 31 March 2025:
Profit for the year
-
-
-
516,190
516,190
Other comprehensive income:
Revaluation of tangible fixed assets
-
19,708,457
-
-
19,708,457
Tax relating to other comprehensive income
-
(4,431,124)
-
-
0
(4,431,124)
Total comprehensive income
-
15,277,333
-
516,190
15,793,523
Balance at 31 March 2025
5,000,000
53,296,057
38,304
15,040,254
73,374,615
ADVINIA HEALTH CARE LIMITED
COMPANY STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 MARCH 2025
- 16 -
Share capital
Revaluation reserve
Profit and loss reserves
Total
£
£
£
£
Balance at 1 April 2023
5,000,000
1,404,809
1,377,863
7,782,672
Year ended 31 March 2024:
Loss for the year
-
-
(782,763)
(782,763)
Other comprehensive income:
Revaluation of tangible fixed assets
-
10,367,977
-
10,367,977
Tax relating to other comprehensive income
-
(2,591,994)
-
0
(2,591,994)
Total comprehensive income
-
7,775,983
(782,763)
6,993,220
Balance at 31 March 2024
5,000,000
9,180,792
595,100
14,775,892
Year ended 31 March 2025:
Profit for the year
-
-
(10,266)
(10,266)
Other comprehensive income:
Revaluation of tangible fixed assets
-
3,643,098
-
3,643,098
Tax relating to other comprehensive income
-
(910,774)
-
0
(910,774)
Total comprehensive income
-
2,732,324
(10,266)
2,722,058
Balance at 31 March 2025
5,000,000
11,913,116
584,834
17,497,950
ADVINIA HEALTH CARE LIMITED
GROUP STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 MARCH 2025
- 17 -
2025
2024
Notes
£
£
£
£
Cash flows from operating activities
Cash generated from operations
27
12,133,462
10,851,760
Interest paid
(3,707,000)
(3,879,541)
Income taxes paid
(215,586)
(81,284)
Net cash inflow from operating activities
8,210,876
6,890,935
Investing activities
Purchase of intangible assets
(207,716)
(46,882)
Purchase of tangible fixed assets
(4,141,027)
(1,924,465)
Repayment of loans
(165,444)
(745,978)
Interest received
38,589
37,030
Net cash used in investing activities
(4,475,598)
(2,680,295)
Financing activities
Repayment of borrowings
(170,676)
(1,547,337)
Repayment of bank loans
(2,550,000)
(2,550,000)
Payment of finance leases obligations
(47,679)
(40,326)
Net cash used in financing activities
(2,768,355)
(4,137,663)
Net increase in cash and cash equivalents
966,923
72,977
Cash and cash equivalents at beginning of year
3,374,755
3,301,778
Cash and cash equivalents at end of year
4,341,678
3,374,755
Relating to:
Cash at bank and in hand
4,345,239
3,374,755
Bank overdrafts included in creditors payable within one year
(3,561)
-
ADVINIA HEALTH CARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
- 18 -
1
Accounting policies
Company information

Advinia Health Care Limited (“the company”) is a private limited company domiciled and incorporated in England and Wales. The registered office is Gateway House (First Floor), 324 Regents Park Road, London, N3 2LN.

 

The group consists of Advinia Health Care Limited and all of its subsidiaries.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, modified to include the revaluation of freehold properties and certain financial instruments at fair value. The principal accounting policies adopted are set out below.

As permitted by s408 Companies Act 2006, the company has not presented its own profit and loss account and related notes.

 

For the year ending 31 March 2025 the wholly owned subsidiaries of Advinia Health Care Limited disclosed under note 16, claimed an exemption from audit under section 479A of the Companies Act 2006 relating to subsidiary companies.

1.2
Basis of consolidation

The consolidated group financial statements consist of the financial statements of the parent company Advinia Health Care Limited together with all entities controlled by the parent company (its subsidiaries) and the group’s share of its interests in joint ventures and associates.

 

All financial statements are made up to 31 March 2025. Where necessary, adjustments are made to the financial statements of subsidiaries to bring the accounting policies used into line with those used by other members of the group.

 

All intra-group transactions, balances and unrealised gains on transactions between group companies are eliminated on consolidation. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred.

Subsidiaries are consolidated in the group’s financial statements from the date that control commences until the date that control ceases.

Entities in which the group holds an interest and which are jointly controlled by the group and one or more other venturers under a contractual arrangement are treated as joint ventures. Entities other than subsidiary undertakings or joint ventures, in which the group has a participating interest and over whose operating and financial policies the group exercises a significant influence, are treated as associates.

ADVINIA HEALTH CARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
1
Accounting policies
(Continued)
- 19 -
1.3
Going concern

In arriving at their conclusion on the going concern status of the business, management have considered the group's financial position and given careful attention to its net current liability position at the balance sheet date.

 

The group meets its day to day working capital requirements through operating cash flows and through facilities provided by its stakeholders. If necessary, shareholders are willing to provide further financial support as they have done in the past.

 

Accordingly, and having reviewed the group financial forecasts and expected future cash flows, the directors have a reasonable expectation that the company and group have adequate resources available to it to continue in operational existence for the foreseeable future, a period of not less than 12 months from the date of signing of these financial statements.

 

Based on this, the directors believe that it remains appropriate to prepare the financial statements on a going concern basis. The financial statements do not include any adjustments that would result from the basis of preparation being inappropriate.

1.4
Turnover

Turnover represents amounts receivable for the provision of services in relation to the care homes. Income is recognised on the day the service is provided.

1.5
Research and development expenditure

Research expenditure is written off against profits in the year in which it is incurred. Identifiable development expenditure is capitalised to the extent that the technical, commercial and financial feasibility can be demonstrated.

1.6
Intangible fixed assets - goodwill

Goodwill represents the excess of the cost of acquisition of a business over the fair value of net assets acquired. It is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

 

Negative goodwill represents the excess of fair value of net assets acquired over the cost of acquisition of a business. It is recognised separately as part of the goodwill balance and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

 

Goodwill is considered to have a finite useful life and is amortised on a systematic basis over its expected life, which has been estimated at 5 years for the negative goodwill and 10 years for the positive goodwill.

1.7
Intangible fixed assets other than goodwill

Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Software
20 years - Straight Line
Development costs
20 years - Straight Line
1.8
Tangible fixed assets

Tangible fixed assets, with the exception of freehold property, are measured using the cost model. These assets are stated at historical cost less accumulated depreciation and any accumulated impairment losses.

ADVINIA HEALTH CARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
1
Accounting policies
(Continued)
- 20 -

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Freehold land and buildings
2% straight line on the value of buildings
Fixtures and fittings
Between 3 and 50 years straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the profit and loss account.

1.9
Fixed asset investments

In the parent company financial statements, investments in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses.

A subsidiary is an entity controlled by the group. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

1.10
Impairment of fixed assets

At each reporting period end date, the group reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

 

The carrying amount of the investments accounted for using the equity method is tested for impairment as a single asset. Any goodwill included in the carrying amount of the investment is not tested separately for impairment.

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

 

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

1.11
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

ADVINIA HEALTH CARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
1
Accounting policies
(Continued)
- 21 -
1.12
Financial instruments

The group has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the group's balance sheet when the group becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset and the net amounts presented in the financial statements when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Other financial assets

Other financial assets, including investments in equity instruments which are not subsidiaries, associates or joint ventures, are initially measured at fair value, which is normally the transaction price. Such assets are subsequently carried at fair value and the changes in fair value are recognised in profit or loss, except that investments in equity instruments that are not publicly traded and whose fair values cannot be measured reliably are measured at cost less impairment.

Impairment of financial assets

Financial assets, other than those held at fair value through profit and loss, are assessed for indicators of impairment at each reporting end date.

 

Financial assets are impaired where there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows have been affected. If an asset is impaired, the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in profit or loss.

 

If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been, had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.

Derecognition of financial assets

Financial assets are derecognised only when the contractual rights to the cash flows from the asset expire or are settled, or when the group transfers the financial asset and substantially all the risks and rewards of ownership to another entity, or if some significant risks and rewards of ownership are retained but control of the asset has transferred to another party that is able to sell the asset in its entirety to an unrelated third party.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the group after deducting all of its liabilities.

ADVINIA HEALTH CARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
1
Accounting policies
(Continued)
- 22 -
Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the group's contractual obligations expire or are discharged or cancelled.

1.13
Equity instruments

Equity instruments issued by the group are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the group.

1.14
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The group’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset if, and only if, there is a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

ADVINIA HEALTH CARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
1
Accounting policies
(Continued)
- 23 -
1.15
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.16
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.17
Leases

Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessees. All other leases are classified as operating leases.

 

Assets held under finance leases are recognised as assets at the lower of the assets fair value at the date of inception and the present value of the minimum lease payments. The related liability is included in the balance sheet as a finance lease obligation. Lease payments are treated as consisting of capital and interest elements. The interest is charged to profit or loss so as to produce a constant periodic rate of interest on the remaining balance of the liability.

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leased asset are consumed.

1.18
Government grants

Government grants are recognised at the fair value of the asset received or receivable when there is reasonable assurance that the grant conditions will be met and the grants will be received.

 

A grant that specifies performance conditions is recognised in income when the performance conditions are met. Where a grant does not specify performance conditions it is recognised in income when the proceeds are received or receivable. A grant received before the recognition criteria are satisfied is recognised as a liability.

ADVINIA HEALTH CARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 24 -
2
Judgements and key sources of estimation uncertainty

In the application of the group’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

Critical judgements

The following judgements (apart from those involving estimates) have had the most significant effect on amounts recognised in the financial statements.

Fair Value of Land and buildings

The group's land and buildings are measured using the fair value model and stated at their fair value as at the reporting date. The directors have used market evidence to assess an appropriate value at the year end.

Amortisation and depreciation

The directors estimate the useful lives and residual values of goodwill and property, plant & equipment in order to calculate the amortisation and depreciation charges. Changes in these estimates could result in changes being required to the annual charges in the Statement of Comprehensive Income and the carrying values of these assets in the Balance Sheet.

Impairment of assets

The group assesses at each reporting date whether there is an indication that an asset may be impaired. If any such indication exists, or when annual impairment testing for an asset is required, the group makes an estimate of the asset's recoverable amount. An asset's recoverable amount is the higher of an asset's or cash-generating unit's fair value less costs to sell and its value in use and is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets.

 

Where the carrying amount of an asset exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount. In assessing value in use, the estimated future cash flows are discounted to their present value and any risks specific to the asset are also assessed. Impairment losses of continuing operations are recognized in the profit or loss in those expense categories consistent with the function of the impaired asset.

Deferred tax liability

The group estimates future profitability in arriving at the fair value of the deferred tax assets and liabilities. If the final tax outcome is different to the estimated deferred tax amount, the resulting changes will be reflected in the statement of comprehensive income, unless the tax relates to an item charged to equity in which case the changes in tax estimates will also be reflected in equity.

3
Turnover and other revenue
2025
2024
£
£
Turnover analysed by class of business
Care homes
97,394,339
97,150,651
ADVINIA HEALTH CARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
3
Turnover and other revenue
(Continued)
- 25 -
2025
2024
£
£
Turnover analysed by geographical market
United Kingdom
97,394,339
97,150,651
2025
2024
£
£
Other revenue
Interest income
38,589
37,030
4
Administrative expenses
2025
2024
£
£
Support office costs
6,727,841
6,681,543
Depreciation
5,672,934
5,703,419
Amortisation
594,445
98,188
Negative amortisation
-
(2,959,274)
Other admin costs and one off items
5,460,347
4,835,275
18,455,567
14,359,151
5
Net profit
2025
2024
£
£
Net profit for the year is stated after charging:
Depreciation of owned tangible fixed assets
5,672,934
5,703,417
Amortisation of intangible assets
594,445
(2,861,085)
Operating lease charges
997,227
969,705
6
Auditor's remuneration
2025
2024
Fees payable to the company's auditor and associates:
£
£
For audit services
Audit of the financial statements of the group and company
60,000
58,000
For other services
All other non-audit services
30,000
28,500
ADVINIA HEALTH CARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
6
Auditor's remuneration
(Continued)
- 26 -

Limitation of auditor's liability

 

On 7 October 2025 the board of directors convened a meeting to agree the proposal to limit the liability of the Auditor in the event of any claim for loss or damage arising from their professional services provided.

 

The auditors limitation of liability shall be £500,000 (or ten times the annual fee if greater). The sum representing the maximum total lability to the Company in respect of the Auditor, its principals, members and staff.

7
Employees

The average monthly number of persons (including directors) employed by the group and company during the year was:

Group
Company
2025
2024
2025
2024
Number
Number
Number
Number
2,650
2,570
123
120

Their aggregate remuneration comprised:

Group
Company
2025
2024
2025
2024
£
£
£
£
Wages and salaries
57,332,460
59,393,755
5,244,339
5,039,299
Social security costs
4,839,006
4,656,722
636,385
655,958
Pension costs
1,030,204
914,120
152,559
31,054
63,201,670
64,964,597
6,033,283
5,726,311
8
Directors' remuneration
2025
2024
£
£
Remuneration for qualifying services
301,129
300,000
Remuneration disclosed above includes the following amounts paid to the highest paid director:
2025
2024
£
£
Remuneration for qualifying services
151,129
150,000
ADVINIA HEALTH CARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 27 -
9
Interest receivable and similar income
2025
2024
£
£
Interest income
Interest on bank deposits
38,589
37,030
2025
2024
Investment income includes the following:
£
£
Interest on financial assets not measured at fair value through profit or loss
38,589
37,030
10
Interest payable and similar expenses
2025
2024
£
£
Interest on financial liabilities measured at amortised cost:
Interest on bank overdrafts and loans
3,527,579
3,846,559
Other finance costs:
Finance costs for financial instruments measured at fair value through profit or loss
170,676
1,547,337
Other interest
1,181
39,519
Total finance costs
3,699,436
5,433,415
11
Amounts written off investments
2025
2024
£
£
Amounts written off current loans
(165,444)
(745,978)
12
Taxation
2025
2024
£
£
Current tax
UK corporation tax on profits for the current period
135,310
-
0
Adjustments in respect of prior periods
-
0
201,075
Total current tax
135,310
201,075
Deferred tax
Origination and reversal of timing differences
431,900
-
0
Total tax charge
567,210
201,075
ADVINIA HEALTH CARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
12
Taxation
(Continued)
- 28 -

The actual charge for the year can be reconciled to the expected charge for the year based on the profit or loss and the standard rate of tax as follows:

2025
2024
£
£
Profit before taxation
1,083,400
1,954,730
Expected tax charge based on the standard rate of corporation tax in the UK of 25.00% (2024: 25.00%)
270,850
488,683
Tax effect of expenses that are not deductible in determining taxable profit
41,361
10,418
Tax effect of income not taxable in determining taxable profit
(36,673)
-
0
Tax effect of utilisation of tax losses not previously recognised
(4,706)
(352,489)
Group relief
(202,281)
(89,791)
Permanent capital allowances in excess of depreciation
(1,351,669)
(770,189)
Depreciation on assets not qualifying for tax allowances
1,418,428
1,425,854
Amortisation on assets not qualifying for tax allowances
-
0
(712,486)
Under/(over) provided in prior years
-
0
201,075
Deferred tax
431,900
-
0
Taxation charge
567,210
201,075

In addition to the amount charged to the profit and loss account, the following amounts relating to tax have been recognised directly in other comprehensive income:

2025
2024
£
£
Deferred tax arising on:
Revaluation of property
4,431,124
3,166,201

The deferred tax provision on Land and Buidlings has been revised in line with the increase in corporation tax rates.

ADVINIA HEALTH CARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 29 -
13
Non-recurring items
2025
2024
£
£
IT intergration costs
-
109,656
Legal and professional fees
1,272,966
746,356
Restructure costs
691,147
666,554
Other costs
1,273,313
1,553,040
Total
3,237,426
3,075,606

Non-recurring costs relate to one-off legal and professional fees as well as costs incurred due to group restructuring.

14
Intangible fixed assets
Group
Goodwill
Negative goodwill
Software
Development costs
Total
£
£
£
£
£
Cost
At 1 April 2024
6,059,865
(16,972,892)
299,171
2,015,411
(8,598,445)
Additions - internally developed
-
0
-
0
69
186,288
186,357
Additions - separately acquired
-
0
-
0
21,358
-
0
21,358
At 31 March 2025
6,059,865
(16,972,892)
320,598
2,201,699
(8,390,730)
Amortisation and impairment
At 1 April 2024
6,059,865
(16,972,891)
34,778
315,468
(10,562,780)
Amortisation charged for the year
-
0
-
0
66,188
528,257
594,445
At 31 March 2025
6,059,865
(16,972,891)
100,966
843,725
(9,968,335)
Carrying amount
At 31 March 2025
-
0
(1)
219,632
1,357,974
1,577,605
At 31 March 2024
-
0
(1)
264,393
1,699,943
1,964,335
ADVINIA HEALTH CARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
14
Intangible fixed assets
(Continued)
- 30 -
Company
Software
Development costs
Total
£
£
£
Cost
At 1 April 2024
75,663
1,938,908
2,014,571
Additions - internally developed
-
0
123,585
123,585
At 31 March 2025
75,663
2,062,493
2,138,156
Amortisation and impairment
At 1 April 2024
8,682
311,416
320,098
Amortisation charged for the year
8,474
519,999
528,473
At 31 March 2025
17,156
831,415
848,571
Carrying amount
At 31 March 2025
58,507
1,231,078
1,289,585
At 31 March 2024
66,981
1,627,492
1,694,473

More information on impairment movements in the year is given in note .

15
Tangible fixed assets
Group
Freehold land and buildings
Fixtures and fittings
Total
£
£
£
Cost or valuation
At 1 April 2024
121,024,968
41,291,584
162,316,552
Additions
-
0
4,141,027
4,141,027
Revaluation
19,708,457
-
0
19,708,457
At 31 March 2025
140,733,425
45,432,611
186,166,036
Depreciation and impairment
At 1 April 2024
334,226
24,143,104
24,477,330
Depreciation charged in the year
2,122,726
3,550,208
5,672,934
At 31 March 2025
2,456,952
27,693,312
30,150,264
Carrying amount
At 31 March 2025
138,276,473
17,739,299
156,015,772
At 31 March 2024
120,690,742
17,148,480
137,839,222
ADVINIA HEALTH CARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
15
Tangible fixed assets
(Continued)
- 31 -
Company
Freehold land and buildings
Fixtures and fittings
Total
£
£
£
Cost or valuation
At 1 April 2024
26,290,676
5,242,995
31,533,671
Additions
-
0
1,943,901
1,943,901
Revaluation
3,643,098
-
0
3,643,098
At 31 March 2025
29,933,774
7,186,896
37,120,670
Depreciation and impairment
At 1 April 2024
-
0
4,565,261
4,565,261
Depreciation charged in the year
69,949
214,677
284,626
At 31 March 2025
69,949
4,779,938
4,849,887
Carrying amount
At 31 March 2025
29,863,825
2,406,958
32,270,783
At 31 March 2024
26,290,676
677,734
26,968,410

Land and buildings were revalued on 20 December 2024 by Colliers, independent Registered Chartered Surveyors who are not connected with the company.

 

The valuation was based on the following assumptions:

 

 

 

16
Fixed asset investments
Group
Company
2025
2024
2025
2024
Notes
£
£
£
£
Investments in subsidiaries
17
-
0
-
0
57,538,498
57,536,198
ADVINIA HEALTH CARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
16
Fixed asset investments
(Continued)
- 32 -
Movements in fixed asset investments
Company
Shares in subsidiaries
£
Cost or valuation
At 1 April 2024
57,536,198
Additions
2,300
At 31 March 2025
57,538,498
Carrying amount
At 31 March 2025
57,538,498
At 31 March 2024
57,536,198
ADVINIA HEALTH CARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 33 -
17
Subsidiaries

Details of the company's subsidiaries at 31 March 2025 are as follows:

Name of undertaking
Registered office
Class of
% Held
shares held
Direct
Roseacres Care Home Limited
England & Wales
Ordinary
100.00
Annan Court Care Home Limited
England & Wales
Ordinary
100.00
Goldielea Care Home Limited
England & Wales
Ordinary
100.00
Kingsway Care Home Limited
England & Wales
Ordinary
100.00
Priory Supporting Care Limited
England & Wales
Ordinary
100.00
Woodstock Care Home Limited
England & Wales
Ordinary
100.00
Woodfield Care Home Limited
England & Wales
Ordinary
100.00
Madeira Care Home Limited
England & Wales
Ordinary
100.00
Maycroft Care Home Limited
England & Wales
Ordinary
100.00
Advinia Care Homes Limited
England & Wales
Ordinary
100.00
Arncliffe Court Limited
England & Wales
Ordinary
100.00
Bedford Care Home Limited
England & Wales
Ordinary
100.00
Braemount Care Home Limited
England & Wales
Ordinary
100.00
Burrswood House Care Home Limited
England & Wales
Ordinary
100.00
Cloisters Care Home Limited
England & Wales
Ordinary
100.00
Craigbank Care Home Limited
England & Wales
Ordinary
100.00
Deanfield Care Home Limited
England & Wales
Ordinary
100.00
Elderslie Care Home Limited
England & Wales
Ordinary
100.00
Golfhill Care Home Limited
England & Wales
Ordinary
100.00
Gorton Parks Care Home Limited
England & Wales
Ordinary
100.00
Hammerwich Hall Care Home Limited
England & Wales
Ordinary
100.00
Haydale Care Home Limited
England & Wales
Ordinary
100.00
Mill View Bolton Limited
England & Wales
Ordinary
100.00
Mill View Glasgow Limited
England & Wales
Ordinary
100.00
Netherton Green Care Home Limited
England & Wales
Ordinary
100.00
Newcarron Care Home Limited
England & Wales
Ordinary
100.00
Norwood Care Home Limited
England & Wales
Ordinary
100.00
Parklands Court Care Home Limited
England & Wales
Ordinary
100.00
Rutherglen Care Home Limited
England & Wales
Ordinary
100.00
Ryland View Care Home Limited
England & Wales
Ordinary
100.00
Stonedale Lodge Care Home Limited
England & Wales
Ordinary
100.00
West Ridings Care Homes Limited
England & Wales
Ordinary
100.00
Hill View Care Home (Clydebank) Limited
England & Wales
Ordinary
100.00
ADVINIA HEALTH CARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 34 -
18
Debtors
Group
Company
2025
2024
2025
2024
Amounts falling due within one year:
£
£
£
£
Trade debtors
2,833,257
4,773,198
301,488
282,741
Corporation tax recoverable
6,036
-
0
-
0
-
0
Other debtors
1,000,256
777,099
357,786
115,514
Prepayments and accrued income
2,105,046
2,231,340
129,654
79,600
5,944,595
7,781,637
788,928
477,855
19
Creditors: amounts falling due within one year
Group
Company
2025
2024
2025
2024
Notes
£
£
£
£
Bank loans and overdrafts
21
2,553,561
2,550,000
2,550,000
2,550,000
Obligations under finance leases
88,653
55,625
88,653
55,625
Trade creditors
5,392,650
7,781,484
748,406
1,029,015
Corporation tax payable
135,310
209,550
-
0
187,373
Other taxation and social security
1,050,272
1,259,860
160,984
170,736
Deferred income
1,792,959
1,553,844
-
0
-
0
Other creditors
2,931,966
3,146,632
671,080
819,359
Accruals
3,434,275
1,925,228
375,009
431,814
17,379,646
18,482,223
4,594,132
5,243,922
20
Creditors: amounts falling due after more than one year
Group
Company
2025
2024
2025
2024
Notes
£
£
£
£
Bank loans and overdrafts
21
40,800,000
43,350,000
40,800,000
43,350,000
Obligations under finance leases
-
0
80,707
-
0
80,707
Other borrowings
21
13,030,574
13,030,574
9,154,191
9,154,191
Amounts owed to group undertakings
-
0
-
0
19,169,207
13,184,438
53,830,574
56,461,281
69,123,398
65,769,336
ADVINIA HEALTH CARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 35 -
21
Loans and overdrafts
Group
Company
2025
2024
2025
2024
£
£
£
£
Bank loans
43,350,000
45,900,000
43,350,000
45,900,000
Bank overdrafts
3,561
-
0
-
0
-
0
Loans from related parties
13,030,574
13,030,574
9,154,191
9,154,191
56,384,135
58,930,574
52,504,191
55,054,191
Payable within one year
2,553,561
2,550,000
2,550,000
2,550,000
Payable after one year
53,830,574
56,380,574
49,954,191
52,504,191

On 31 January 2021, the group entered into a new senior facilities agreement with Natwest for £54,000,000. The facility comprises of a term loan facility of £51,000,000 and a revolving facility of £3,000,000. The facilities bear interest at the SONIA rate plus a margin between 2.35% and 3.15%. The actual margin applied is based on the quarterly loan leverage ratio with 2.35% being the minimum and 3.15% being the maximum margin.

 

The loan is repayable on a quarterly basis by the amounts of £637,500 from 31 July 2022 until the termination date on 31 January 2027, at which point the outstanding liability of £38,887,500 will fall due.

22
Deferred taxation

The following are the major deferred tax liabilities and assets recognised by the group and company, and movements thereon:

Liabilities
Liabilities
2025
2024
Group
£
£
Accelerated capital allowances
1,955,983
1,857,799
Revaluations
21,342,393
16,577,553
23,298,376
18,435,352
Liabilities
Liabilities
2025
2024
Company
£
£
Accelerated capital allowances
241,067
142,883
Revaluations
3,836,484
2,591,994
4,077,551
2,734,877
ADVINIA HEALTH CARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
22
Deferred taxation
(Continued)
- 36 -
Group
Company
2025
2025
Movements in the year:
£
£
Liability at 1 April 2024
18,435,352
2,734,877
Charge to profit or loss
431,900
431,900
Charge to other comprehensive income
4,431,124
910,774
Liability at 31 March 2025
23,298,376
4,077,551

Deferred tax on revaluations would only become payable if the revalued fixed assets were to be sold at their carrying value.

23
Retirement benefit schemes
2025
2024
Defined contribution schemes
£
£
Charge to profit or loss in respect of defined contribution schemes
1,030,204
914,120

A defined contribution pension scheme is operated for all qualifying employees. The assets of the scheme are held separately from those of the group in an independently administered fund.

24
Share capital
Group and company
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary shares of £1 each
5,000,000
5,000,000
5,000,000
5,000,000
25
Related party transactions

The group and company have taken advantage of the exemption under terms of FRS102 not to disclose related party transactions with wholly owned subsidiaries within the group.

 

As at 31 March 2025, the group's balance sheet included a payable of £13,030,574 (2024: £13,030,574) due to St Carmen Limited, the group's immediate parent company which is incorporated in Gibraltar.

26
Controlling party

The ultimate controlling parties are the trustees of the Paraman Trust Settlement.

 

ADVINIA HEALTH CARE LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 37 -
27
Cash generated from group operations
2025
2024
£
£
Profit after taxation
516,190
1,753,655
Adjustments for:
Taxation charged
567,210
201,075
Finance costs
3,699,436
5,433,415
Investment income
(38,660)
(37,028)
Amortisation and impairment of intangible assets
594,445
(2,861,085)
Depreciation and impairment of tangible fixed assets
5,672,936
5,703,417
Other gains and losses
165,444
745,978
Movements in working capital:
Decrease in debtors
1,843,078
4,247,926
Decrease in creditors
(1,125,802)
(5,018,266)
Increase in deferred income
239,114
682,675
Cash generated from operations
12,133,391
10,851,762
28
Analysis of changes in net debt - group
1 April 2024
Cash flows
Market value movements
31 March 2025
£
£
£
£
Cash at bank and in hand
3,374,755
970,484
-
4,345,239
Bank overdrafts
-
0
(3,561)
-
(3,561)
3,374,755
966,923
-
4,341,678
Borrowings excluding overdrafts
(58,930,574)
2,720,676
(170,676)
(56,380,574)
Obligations under finance leases
(136,332)
47,679
-
(88,653)
(55,692,151)
3,735,278
(170,676)
(52,127,549)
29
Auditor's liability limitation agreement

It was resolved on 7 October 2025 that in the event of any claim for loss or damage arising from the professional services provided by the Auditor, the Auditor’s limitation of liability for audit shall be £500,000 (or ten times the annual fee if greater). The sum representing the maximum total liability to Advinia Health Care Ltd in respect of the Auditor, its principals, members and staff; this maximum total liability applies to any and all claims made on any basis and therefore includes any claims in respect of breaches of contract, tort (including negligence) or otherwise in respect of the professional services and shall also include interest.

2025-03-312024-04-01falsefalseCCH SoftwareCCH Accounts Production 2025.300Dr S KanoriaMrs S KanoriaMr A VermaMr MW Freerfalse2650257003446822bus:Consolidated2024-04-012025-03-31034468222024-04-012025-03-3103446822bus:Director12024-04-012025-03-3103446822bus:Director22024-04-012025-03-3103446822bus:Director32024-04-012025-03-3103446822bus:Director42024-04-012025-03-3103446822bus:RegisteredOffice2024-04-012025-03-31034468222025-03-3103446822bus:Consolidated2023-04-012024-03-31034468222023-04-012024-03-3103446822core:RevaluationReservebus:Consolidated2023-04-012024-03-3103446822core:RevenueReservesInvestmentFundsOnlybus:Consolidated2023-04-012024-03-3103446822core:RevaluationReservebus:Consolidated2024-04-012025-03-3103446822core:RetainedEarningsAccumulatedLossesbus:Consolidated2024-04-012025-03-3103446822core:RevaluationReserve2023-04-012024-03-3103446822core:RetainedEarningsAccumulatedLosses2023-04-012024-03-3103446822core:RevaluationReserve2024-04-012025-03-3103446822core:RetainedEarningsAccumulatedLosses2024-04-012025-03-3103446822bus:Consolidated2025-03-3103446822core:NegativeGoodwillbus:Consolidated2025-03-3103446822core:NegativeGoodwillbus:Consolidated2024-03-3103446822core:IntangibleAssetsOtherThanGoodwillbus:Consolidated2025-03-3103446822core:IntangibleAssetsOtherThanGoodwillbus:Consolidated2024-03-3103446822bus:Consolidated2024-03-31034468222024-03-3103446822core:Goodwillbus:Consolidated2025-03-3103446822core:ComputerSoftwarebus:Consolidated2025-03-3103446822core:DevelopmentCostsCapitalisedDevelopmentExpenditurebus:Consolidated2025-03-3103446822core:Goodwillbus:Consolidated2024-03-3103446822core:ComputerSoftwarebus:Consolidated2024-03-3103446822core:DevelopmentCostsCapitalisedDevelopmentExpenditurebus:Consolidated2024-03-3103446822core:ComputerSoftware2025-03-3103446822core:DevelopmentCostsCapitalisedDevelopmentExpenditure2025-03-3103446822core:ComputerSoftware2024-03-3103446822core:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-03-3103446822core:LandBuildingscore:OwnedOrFreeholdAssetsbus:Consolidated2025-03-3103446822core:FurnitureFittingsbus:Consolidated2025-03-3103446822core:LandBuildingscore:OwnedOrFreeholdAssetsbus:Consolidated2024-03-3103446822core:FurnitureFittingsbus:Consolidated2024-03-3103446822core:LandBuildingscore:OwnedOrFreeholdAssets2025-03-3103446822core:FurnitureFittings2025-03-3103446822core:LandBuildingscore:OwnedOrFreeholdAssets2024-03-3103446822core:FurnitureFittings2024-03-3103446822core:CurrentFinancialInstrumentscore:WithinOneYearbus:Consolidated2025-03-3103446822core:CurrentFinancialInstrumentsbus:Consolidated2024-03-3103446822core:ShareCapitalbus:Consolidated2025-03-3103446822core:ShareCapitalbus:Consolidated2024-03-3103446822core:RevaluationReservebus:Consolidated2025-03-3103446822core:RevaluationReservebus:Consolidated2024-03-3103446822core:OtherMiscellaneousReservebus:Consolidated2025-03-3103446822core:OtherMiscellaneousReservebus:Consolidated2024-03-3103446822core:RetainedEarningsAccumulatedLossesbus:Consolidated2025-03-3103446822core:RetainedEarningsAccumulatedLossesbus:Consolidated2024-03-3103446822core:ShareCapital2025-03-3103446822core:ShareCapital2024-03-3103446822core:RevaluationReserve2025-03-3103446822core:RevaluationReserve2024-03-3103446822core:RetainedEarningsAccumulatedLosses2025-03-3103446822core:RetainedEarningsAccumulatedLosses2024-03-3103446822core:ShareCapitalbus:Consolidated2023-03-3103446822core:SharePremiumbus:Consolidated2023-03-31034468222023-03-3103446822core:ShareCapital2023-03-3103446822core:RevaluationReserve2023-03-3103446822core:RetainedEarningsAccumulatedLosses2023-03-3103446822bus:Consolidated2023-03-3103446822core:Goodwill2024-04-012025-03-3103446822core:IntangibleAssetsOtherThanGoodwill2024-04-012025-03-3103446822core:ComputerSoftware2024-04-012025-03-3103446822core:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-04-012025-03-3103446822core:LandBuildingscore:OwnedOrFreeholdAssets2024-04-012025-03-3103446822core:FurnitureFittings2024-04-012025-03-3103446822core:UKTaxbus:Consolidated2024-04-012025-03-3103446822core:UKTaxbus:Consolidated2023-04-012024-03-3103446822bus:Consolidated12024-04-012025-03-3103446822bus:Consolidated12023-04-012024-03-3103446822bus:Consolidated22024-04-012025-03-3103446822bus:Consolidated22023-04-012024-03-3103446822bus:Consolidated32024-04-012025-03-3103446822bus:Consolidated32023-04-012024-03-3103446822core:Goodwillbus:Consolidated2024-03-3103446822core:NegativeGoodwillbus:Consolidated2024-03-3103446822core:ComputerSoftwarebus:Consolidated2024-03-3103446822core:DevelopmentCostsCapitalisedDevelopmentExpenditurebus:Consolidated2024-03-3103446822bus:Consolidated2024-03-3103446822core:ComputerSoftware2024-03-3103446822core:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-03-31034468222024-03-3103446822core:Goodwillcore:InternallyGeneratedIntangibleAssetsbus:Consolidated2024-04-012025-03-3103446822core:NegativeGoodwillcore:InternallyGeneratedIntangibleAssetsbus:Consolidated2024-04-012025-03-3103446822core:ComputerSoftwarecore:InternallyGeneratedIntangibleAssetsbus:Consolidated2024-04-012025-03-3103446822core:DevelopmentCostsCapitalisedDevelopmentExpenditurecore:InternallyGeneratedIntangibleAssetsbus:Consolidated2024-04-012025-03-3103446822core:InternallyGeneratedIntangibleAssetsbus:Consolidated2024-04-012025-03-3103446822core:Goodwillcore:ExternallyAcquiredIntangibleAssetsbus:Consolidated2024-04-012025-03-3103446822core:NegativeGoodwillcore:ExternallyAcquiredIntangibleAssetsbus:Consolidated2024-04-012025-03-3103446822core:ComputerSoftwarecore:ExternallyAcquiredIntangibleAssetsbus:Consolidated2024-04-012025-03-3103446822core:DevelopmentCostsCapitalisedDevelopmentExpenditurecore:ExternallyAcquiredIntangibleAssetsbus:Consolidated2024-04-012025-03-3103446822core:ExternallyAcquiredIntangibleAssetsbus:Consolidated2024-04-012025-03-3103446822core:ComputerSoftwarecore:InternallyGeneratedIntangibleAssets2024-04-012025-03-3103446822core:DevelopmentCostsCapitalisedDevelopmentExpenditurecore:InternallyGeneratedIntangibleAssets2024-04-012025-03-3103446822core:InternallyGeneratedIntangibleAssets2024-04-012025-03-3103446822core:Goodwillbus:Consolidated2024-04-012025-03-3103446822core:NegativeGoodwillbus:Consolidated2024-04-012025-03-3103446822core:ComputerSoftwarebus:Consolidated2024-04-012025-03-3103446822core:DevelopmentCostsCapitalisedDevelopmentExpenditurebus:Consolidated2024-04-012025-03-3103446822core:LandBuildingscore:OwnedOrFreeholdAssetsbus:Consolidated2024-03-3103446822core:FurnitureFittingsbus:Consolidated2024-03-3103446822core:LandBuildingscore:OwnedOrFreeholdAssets2024-03-3103446822core:FurnitureFittings2024-03-3103446822core:LandBuildingscore:OwnedOrFreeholdAssetsbus:Consolidated2024-04-012025-03-3103446822core:FurnitureFittingsbus:Consolidated2024-04-012025-03-3103446822core:Subsidiary12024-04-012025-03-3103446822core:Subsidiary22024-04-012025-03-3103446822core:Subsidiary32024-04-012025-03-3103446822core:Subsidiary42024-04-012025-03-3103446822core:Subsidiary52024-04-012025-03-3103446822core:Subsidiary62024-04-012025-03-3103446822core:Subsidiary72024-04-012025-03-3103446822core:Subsidiary82024-04-012025-03-3103446822core:Subsidiary92024-04-012025-03-3103446822core:Subsidiary102024-04-012025-03-3103446822core:Subsidiary112024-04-012025-03-3103446822core:Subsidiary122024-04-012025-03-3103446822core:Subsidiary132024-04-012025-03-3103446822core:Subsidiary142024-04-012025-03-3103446822core:Subsidiary152024-04-012025-03-3103446822core:Subsidiary162024-04-012025-03-3103446822core:Subsidiary172024-04-012025-03-3103446822core:Subsidiary182024-04-012025-03-3103446822core:Subsidiary192024-04-012025-03-3103446822core:Subsidiary202024-04-012025-03-3103446822core:Subsidiary212024-04-012025-03-3103446822core:Subsidiary222024-04-012025-03-3103446822core:Subsidiary232024-04-012025-03-3103446822core:Subsidiary242024-04-012025-03-3103446822core:Subsidiary252024-04-012025-03-3103446822core:Subsidiary262024-04-012025-03-3103446822core:Subsidiary272024-04-012025-03-3103446822core:Subsidiary282024-04-012025-03-3103446822core:Subsidiary292024-04-012025-03-3103446822core:Subsidiary302024-04-012025-03-3103446822core:Subsidiary312024-04-012025-03-3103446822core:Subsidiary322024-04-012025-03-3103446822core:Subsidiary332024-04-012025-03-3103446822core:Subsidiary112024-04-012025-03-3103446822core:Subsidiary222024-04-012025-03-3103446822core:Subsidiary332024-04-012025-03-3103446822core:Subsidiary442024-04-012025-03-3103446822core:Subsidiary552024-04-012025-03-3103446822core:Subsidiary662024-04-012025-03-3103446822core:Subsidiary772024-04-012025-03-3103446822core:Subsidiary882024-04-012025-03-3103446822core:Subsidiary992024-04-012025-03-3103446822core:Subsidiary10102024-04-012025-03-3103446822core:Subsidiary11112024-04-012025-03-3103446822core:Subsidiary12122024-04-012025-03-3103446822core:Subsidiary13132024-04-012025-03-3103446822core:Subsidiary14142024-04-012025-03-3103446822core:Subsidiary15152024-04-012025-03-3103446822core:Subsidiary16162024-04-012025-03-3103446822core:Subsidiary17172024-04-012025-03-3103446822core:Subsidiary18182024-04-012025-03-3103446822core:Subsidiary19192024-04-012025-03-3103446822core:Subsidiary20202024-04-012025-03-3103446822core:Subsidiary21212024-04-012025-03-3103446822core:Subsidiary22222024-04-012025-03-3103446822core:Subsidiary23232024-04-012025-03-3103446822core:Subsidiary24242024-04-012025-03-3103446822core:Subsidiary25252024-04-012025-03-3103446822core:Subsidiary26262024-04-012025-03-3103446822core:Subsidiary27272024-04-012025-03-3103446822core:Subsidiary28282024-04-012025-03-3103446822core:Subsidiary29292024-04-012025-03-3103446822core:Subsidiary30302024-04-012025-03-3103446822core:Subsidiary31312024-04-012025-03-3103446822core:Subsidiary32322024-04-012025-03-3103446822core:Subsidiary33332024-04-012025-03-3103446822core:CurrentFinancialInstrumentsbus:Consolidated2025-03-3103446822core:CurrentFinancialInstruments2025-03-3103446822core:CurrentFinancialInstruments2024-03-3103446822core:CurrentFinancialInstrumentsbus:Consolidated12025-03-3103446822core:CurrentFinancialInstrumentsbus:Consolidated12024-03-3103446822core:CurrentFinancialInstruments22025-03-3103446822core:CurrentFinancialInstruments32025-03-3103446822core:WithinOneYearbus:Consolidated2025-03-3103446822core:WithinOneYearbus:Consolidated2024-03-3103446822core:CurrentFinancialInstrumentscore:WithinOneYear2025-03-3103446822core:CurrentFinancialInstrumentscore:WithinOneYear2024-03-3103446822core:Non-currentFinancialInstrumentscore:AfterOneYearbus:Consolidated2025-03-3103446822core:Non-currentFinancialInstrumentscore:AfterOneYearbus:Consolidated2024-03-3103446822core:Non-currentFinancialInstrumentscore:AfterOneYear2025-03-3103446822core:Non-currentFinancialInstrumentscore:AfterOneYear2024-03-3103446822core:Non-currentFinancialInstrumentsbus:Consolidated2025-03-3103446822core:Non-currentFinancialInstrumentsbus:Consolidated2024-03-3103446822core:Non-currentFinancialInstruments2025-03-3103446822core:Non-currentFinancialInstruments2024-03-3103446822core:CurrentFinancialInstrumentscore:WithinOneYearbus:Consolidated2024-03-3103446822bus:PrivateLimitedCompanyLtd2024-04-012025-03-3103446822bus:FRS1022024-04-012025-03-3103446822bus:Audited2024-04-012025-03-3103446822bus:ConsolidatedGroupCompanyAccounts2024-04-012025-03-3103446822bus:FullAccounts2024-04-012025-03-31xbrli:purexbrli:sharesiso4217:GBP